HC Wainwright Reiterates “Neutral” Rating for Avalo Therapeutics (NASDAQ:AVTX)

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports.

Several other research analysts have also recently weighed in on AVTX. Piper Sandler started coverage on Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. Wedbush reissued an “outperform” rating and set a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday. Finally, BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $35.33.

Avalo Therapeutics Trading Up 2.7 %

Shares of Avalo Therapeutics stock traded up $0.22 during trading on Thursday, hitting $8.21. 18,244 shares of the company’s stock were exchanged, compared to its average volume of 76,732. The business has a 50-day simple moving average of $7.42 and a 200-day simple moving average of $9.11. Avalo Therapeutics has a 52-week low of $4.43 and a 52-week high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares in the last quarter. Marshall Wace LLP acquired a new stake in Avalo Therapeutics during the 4th quarter worth $114,000. Walleye Capital LLC acquired a new position in Avalo Therapeutics during the fourth quarter worth approximately $145,000. Northern Trust Corp acquired a new position in shares of Avalo Therapeutics in the 4th quarter valued at $168,000. Finally, Bank of Montreal Can purchased a new stake in Avalo Therapeutics in the 4th quarter valued at $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.